Islet transplantation in type 1 diabetes: Hype, hope and reality - a clinician's perspective

Diabetes/Metabolism Research and Reviews

Volumn 30, Issue 2, 2014, Pages 83-87

  Zinger, Adar ^a   Leibowitz, Gil ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Hypoglycaemia; Islet transplantation; Type 1 diabetes

Indexed keywords

C PEPTIDE; CALCINEURIN INHIBITOR; DACLIZUMAB; GLUCOSE; INOSINATE DEHYDROGENASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

CANCER RISK; CELL COUNT; CELL VIABILITY; EMBRYONIC STEM CELL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; GRAFT REJECTION; GRAFT SURVIVAL; HEMOPERITONEUM; HISTORY OF MEDICINE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; METABOLIC REGULATION; MORTALITY; NONHUMAN; PANCREAS ISLET CELL FUNCTION; PANCREAS ISLET TRANSPLANTATION; PLURIPOTENT STEM CELL; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; VASCULAR DISEASE;

HYPOGLYCAEMIA; ISLET TRANSPLANTATION; TYPE 1 DIABETES;

ANIMALS; CONGRESSES AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE;

EID: 84893431556     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2484     Document Type: Review

References (34)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
3. Cryer PE. Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42-46.
4. Robertson RP, Davis C, Larsen J, Stratta R, Sutherland DE. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 2006; 29: 935.
5. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972; 72: 175-186.
6. Kemp CB, Knight MJ, Scharp DW, Ballinger WF, Lacy PE. Effect of transplantation site on the results of pancreatic islet isografts in diabetic rats. Diabetologia 1973; 9: 486-491.
7. Najarian JS, Sutherland DE, Baumgartner D, Burke B, Rynasiewicz JJ, et al. Total or near total pancreatectomy and islet autotransplantation for treatment of chronic pancreatitis. Ann Surg 1980; 192: 526-542.
8. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
9. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
10. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012; 35: 1436-1445.
11. Shapiro AM. State of the art of clinical islet transplantation and novel protocols of immunosuppression. Curr Diab Rep 2011; 11: 345-354.
12. The Collaborative Islet Transplant Registry (CITR). Seventh Annual Data R (online report), 2011. Available from http://www.citregistry.org/reports/reports.htm Accessed November 2012.
13. Robertson RP. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010; 59: 1285-1291.
14. Toso C, Shapiro AM, Bowker S, Dinyari P, Paty B, et al. Quality of life after islet transplant: impact of the number of islet infusions and metabolic outcome. Transplantation 2007; 84: 664-666.
15. Thompson DM, Meloche M, Ao Z, Paty B, Keown P, et al. Reduced progression of diabetic microvascular complications with islet cell transplantation compared with intensive medical therapy. Transplantation 2011; 91: 373-378.
16. Fiorina P, Gremizzi C, Maffi P, Caldara R, Tavano D, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 2005; 28: 1358-1365.
17. Shu X, Ji J, Li X, Sundquist J, Sundquist K, et al. Cancer risk among patients hospitalized for Type 1 diabetes mellitus a population-based cohort study in Sweden. Diabet Med 2010; 27: 791-797.
18. Noto H, Osame K, Sasazuki T, Noda M. Substantially increased risk of cancer in patients with diabetes mellitus a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 2010; 24: 345-353.
19. Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, et al. Spectrum of cancer risk among US solid organ transplant recipients. Jama 2011; 306: 1891-1901.
20. Halban PA, German MS, Kahn SE, Weir GC. Current status of islet cell replacement and regeneration therapy. J Clin Endocrinol Metab 2010; 95: 1034-1043.
21. Senior PA, Zeman M, Paty BW, Ryan EA, Shapiro AM. Changes in renal function after clinical islet transplantation: four-year observational study. Am J Transplant 2007; 7: 91-98.
22. Maffi P, Bertuzzi F, De Taddeo F, Magistretti P, Nano R, et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 2007; 30: 1150-1155.
23. Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, et al. Relation between kidney function, proteinuria, and adverse outcomes. Jama 2010; 303: 423-429.
24. Fanelli CG, Pampanelli S, Porcellati F, Bolli GB. Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. Diabetologia 1998; 41: 720-723.
25. Battelino T, Conget I, Olsen B, Schutz-Fuhrmann I, Hommel E, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy a randomised controlled trial. Diabetologia 2012; 55: 3155-3162.
26. de Kort H, de Koning EJ, Rabelink TJ, Bruijn JA, Bajema IM. Islet transplantation in type 1 diabetes. Bmj 2011; 342: d217.
27. Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011; 27: 3-13.
28. Cardona K, Korbutt GS, Milas Z, Lyon J, Cano J, et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nat Med 2006; 12: 304-306.
29. Kroon E, Martinson LA, Kadoya K, Bang AG, Kelly OG, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol 2008; 26: 443-452.
30. Maehr R, Chen S, Snitow M, Ludwig T, Yagasaki L, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A 2009; 106: 15768-15773.
31. Ouziel-Yahalom L, Zalzman M, Anker-Kitai L, Knoller S, Bar Y, et al. Expansion and redifferentiation of adult human pancreatic islet cells. Biochem Biophys Res Commun 2006; 341: 291-298.
32. Sapir T, Shternhall K, Meivar-Levy I, Blumenfeld T, Cohen H, et al. Cell-replacement therapy for diabetes: generating functional insulin-producing tissue from adult human liver cells. Proc Natl Acad Sci U S A 2005; 102: 7964-7969.
33. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008; 455: 627-632.
34. Meier JJ, Butler AE, Saisho Y, Monchamp T, Galasso R, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008; 57: 1584-1594.